Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated ...

The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on February 20, 2026, and its existing cash and ...

Moleculin is currently advancing a Phase 3 clinical trial called MIRACLE, evaluating its lead program Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid ...

HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

The clinical-stage biopharmaceutical company, which focuses on developing novel immunotherapies, approved the exercise of 909,517 special rights for an aggregate subscription price of EUR 1,549,998.87 ...

Japan’s Chugai Pharmaceutical and Swiss ADC specialist Araris Biotech have announced that the Tokyo firm has exercised its option under the research collaboration and option to license agreement (RCO) ...

Moleculin Biotech Inc (NASDAQ:MBRX) saw its stock tumble 34.3% in premarket trading Thursday after announcing agreements with ...

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

A recent study published in the Journal of Nutrition, Health and Aging examined whether combining protein supplementation, ...